Arcoxia
Generic name: etoricoxib
Treatment for: Osteoarthritis
Merck Provides Status Update on Ongoing Arcoxia Trials
WHITEHOUSE STATION, N.J., June 17, 2005 - As previously announced, on Oct. 29, 2004, Merck & Co., Inc. received an "approvable" letter from the U.S. Food and Drug Administration (FDA) for the company's New Drug Application (NDA) for Arcoxia (etoricoxib). The FDA informed Merck in that letter that before approval of the NDA can be issued, additional safety and efficacy data for Arcoxia are required. These data will include data from ongoing clinical trials for Arcoxia, known as MEDAL and EDGE II. These trials are being monitored by a Data Safety Monitoring Board (DSMB) responsible for the ongoing safety of the trials. The DSMB met recently and recommended that the studies continue as planned. Merck remains blinded to the clinical data from these trials.
About Merck
Merck & Co., Inc. is a global research-driven pharmaceutical company dedicated to putting patients first. Established in 1891, Merck discovers, develops, manufactures and markets vaccines and medicines in more than 20 therapeutic categories. The company devotes extensive efforts to increase access to medicines through far-reaching programs that not only donate Merck medicines but help deliver them to the people who need them. Merck also publishes unbiased health information as a not-for-profit service.
For more information, please visit the Merck website.
Posted: June 2005
Related articles
- Merck Receives Non Approvable Letter from FDA for Arcoxia(etoricoxib) - April 27, 2007
- Public Citizen: FDA Should Not Approve "Offspring of Vioxx" Painkiller - April 13, 2007
- FDA Advisory Committee Recommends Against Approval for Merck's NDAfor Arcoxia (etoricoxib) - April 12, 2007
- Statement by Merck & Co., Inc. Regarding FDA Arthritis Drugs Advisory Committee Meeting on Arcoxia (etoricoxib) - April 11, 2007
- Arthritis Foundation Chief Public Health Officer Testifies at FDA Hearing on Arcoxia - April 9, 2007
- Merck Responds to FDA-Issued Approvable Letters for Arcoxia (etoricoxib) - November 10, 2006
- Merck Receives ’Approvable’ Letter for Arcoxia - October 29, 2004
Arcoxia (etoricoxib) FDA Approval History
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
